Scarica l'app Stockscreener
4.95
6.68%
0.31
Dopo l'orario di chiusura:
4.92
-0.03
-0.61%
Precedente Chiudi:
$4.64
Aprire:
$4.46
Volume 24 ore:
325.81K
Relative Volume:
1.72
Capitalizzazione di mercato:
$135.29M
Reddito:
$61.86M
Utile/perdita netta:
$-11.43M
Rapporto P/E:
-10.27
EPS:
-0.4818
Flusso di cassa netto:
$-12.52M
1 W Prestazione:
+3.56%
1M Prestazione:
-38.81%
6M Prestazione:
-32.19%
1 anno Prestazione:
-20.67%
Intervallo 1D:
$4.46
$5.02
Intervallo di 1 settimana:
$4.31
$5.02
Portata 52W:
$4.31
$9.555
Journey Medical Corp Stock (DERM) Company Profile
Nome
Journey Medical Corp
Settore
Telefono
480-434-6670
Indirizzo
9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE
Compare DERM vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DERM
Journey Medical Corp
|
4.95 | 135.29M | 61.86M | -11.43M | -12.52M | -0.4818 |
TAK
Takeda Pharmaceutical Co Adr
|
18.74 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.94 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.93 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.08 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
564.81 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Journey Medical Corp Stock (DERM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-25 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-30 | Ripresa | B. Riley Securities | Buy |
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | ROTH MKM | Buy |
| 2021-12-07 | Iniziato | B. Riley Securities | Buy |
Journey Medical Corp Borsa (DERM) Ultime notizie
Stock List: Research Stocks from Around the World - GuruFocus
DERM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of “Hold” by Analysts - Defense World
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of "Hold" by Analysts - MarketBeat
US Stocks Recap: Can Journey Medical Corporation be the next market leaderPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Short Squeeze: Can Journey Medical Corporation reach all time highs this year2026 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Why The Journey Medical (DERM) Narrative Is Shifting With New Targets And Going Concern Risks - Yahoo Finance
KALA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Update: Can Journey Medical Corporation reach all time highs this yearWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Journey Medical (NASDAQ:DERM) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Journey Medical Corporation (NASDAQ:DERM) Q4 2025 Earnings Call Transcript - Insider Monkey
HC Wainwright Forecasts Journey Medical Q1 Earnings - MarketBeat
Market Pulse: What hedge funds are buying Journey Medical CorporationQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and Journey Medical Corp (DERM) - The Globe and Mail
Journey Medical (DERM) Q4 Results: Examining Essential Metrics Compared to Projections - Bitget
Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Journey Medical Corporation 2025 Annual Report: Dermatology Product Portfolio, FDA Approvals, Market Strategy, and Intellectual Property Overview - minichart.com.sg
Top movers analysis one hour before the close of the markets on 2026-03-26: top gainers and losers in today's session. - ChartMill
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Journey Medical Corporation Q4 2025 Earnings Call Summary - finance.yahoo.com
HC Wainwright Reaffirms Buy Rating for Journey Medical (NASDAQ:DERM) - marketbeat.com
Journey Medical stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Journey Medical 2025 10-K: $61.9M Revenue, $(11.4)M Net Loss - TradingView
Journey Medical Corp (DERM) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
DERM Drops 25%: The Contradiction of a Positive Analyst Rating During Sharp Intraday Decline - Bitget
Journey Medical earnings missed by $0.50, revenue fell short of estimates - Investing.com
Earnings call transcript: Journey Medical reports Q4 2025 growth, EMROSI sales boost - uk.investing.com
Journey Medical Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Journey Medical reports Q4 2025 growth, EMROSI sales boost By Investing.com - Investing.com South Africa
Journey Medical Corp reports results for the quarter ended September 30Earnings Summary - TradingView
Journey Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Journey Medical (Nasdaq: DERM) adds Emrosi rosacea drug and global deals - Stock Titan
Journey posts FY2025 revenue $61.9M, narrowed net loss to $11.4M and reports $2.9M Adjusted EBITDA - TradingView
Journey Medical (NASDAQ: DERM) grows 2025 revenue to $61.9M as losses narrow - stocktitan.net
New rosacea drug drove $14.7M for Journey Medical after April launch - Stock Titan
Rate Cut: Is Journey Medical Corporation undervalued by DCF analysis2026 Drop Watch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Earnings Scheduled For March 25, 2026 - Benzinga
Journey Medical Corp stock faces key test ahead of Q4 2025 earnings release on March 25, 2026 - AD HOC NEWS
Journey Medical Corp (DERM) Q4 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Journey Medical Corp expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Pullback Watch: Is Journey Medical Corporation undervalued by DCF analysisWeekly Investment Recap & Capital Protection Trading Alerts - baoquankhu1.vn
Danone Sets New Sustainability Targets with Second Phase of Impact Journey - Food & Beverage Outlook
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - The Manila Times
WallabyPhenox Restructures Debt and Accelerates Global Growth - The Manila Times
Off The Hook Yachts Expands Mid-Atlantic Presence with Strategic Waterfront Hub to Increase Inventory Velocity and Margin Capture - The Manila Times
Siemens Healthineers Launches Brain Health Research Portfolio with First Biomarker Assays Now Available - The Manila Times
GSI Technology Concludes Strategic Alternatives Review - The Manila Times
Dermatology drug seller Journey Medical to detail 2025 results on Mar. 25 - Stock Titan
Journey Medical (DERM) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
TENX PE Ratio & Valuation, Is TENX Overvalued - Intellectia AI
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Journey Medical Corp Azioni (DERM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):